Theodore Alan Huizenga - 07 Sep 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
SVP, Chief Accounting Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
07 Sep 2023
Net transactions value
-$46,249
Form type
4
Filing time
11 Sep 2023, 13:52:12 UTC
Previous filing
06 Sep 2023
Next filing
29 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Options Exercise $42,000 +2,000 +8.4% $21.00 25,777 07 Sep 2023 Direct F1
transaction RARE Common Stock Sale $82,000 -2,000 -7.8% $41.00 23,777 07 Sep 2023 Direct
transaction RARE Common Stock Sale $6,249 -163 -0.69% $38.34 23,614 07 Sep 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Options Exercise $0 -2,000 -40% $0.000000 3,000 07 Sep 2023 Common Stock 2,000 $21.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
F2 Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.
F3 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter.